Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Can Fite BioPharma Ltd | CANF | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.98 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.68 - 3.33 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.98 | USD |
Can Fite BioPharma Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
0 | 1.50B | - | 743k | -7.63M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Can Fite BioPharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CANF Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.07 | 2.2909 | 1.91 | 1.99 | 14,396 | -0.09 | -4.35% |
1 Month | 2.22 | 2.71 | 1.91 | 2.22 | 19,154 | -0.24 | -10.81% |
3 Months | 2.21 | 2.71 | 1.91 | 2.15 | 19,700 | -0.23 | -10.41% |
6 Months | 2.03 | 2.80 | 1.81 | 2.14 | 59,086 | -0.05 | -2.46% |
1 Year | 1.75 | 3.33 | 1.68 | 2.23 | 40,737 | 0.23 | 13.14% |
3 Years | 22.20 | 26.20 | 1.52 | 17.19 | 462,676 | -20.22 | -91.08% |
5 Years | 5.10 | 88.765 | 1.52 | 21.51 | 730,228 | -3.12 | -61.18% |
Can Fite BioPharma Description
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). |